FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Big Software Firms Offer AI Discounts in Bid to Counter Anthropic, OpenAI

By

Amazon (AMZN), Microsoft (MSFT), Figma (FIG), Workday (WDAY) and other big software firms are offering discounts on AI products to retain customers and prevent them from turning to Anthropic and OpenAI, The Information reported Tuesday, citing its own reporting and sources.

Adobe (ADBE) is offering free access for AI products like Adobe Firefly, while Amazon is offering 90-day free trials for its AI assistant, Amazon Quick. Figma has cut the costs of credits to use AI products like Figma Make, while HubSpot (HUBS) is providing free trials to try AI agents like Breeze Assistant. Finally, Microsoft is offering discounts for Copilot subscription costs, and Workday is letting top customers use its AI platform for free for one year, the report said.

The companies didn't immediately reply to requests for comment from.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: $257.03, Change: $-1.43, Percent Change: -0.55%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA